Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Drugs to avoid: 2021 update
• Spotlight

About Prescrire

• Who are we?
• How we work
• AMP: non-profit
• Financing
• "Non merci"
• Where to find us
• About Prescrire International
• Testimonials
• Prescrire events
• A global network

Offers

• Subscribe now
• Solidarity Subscription Rate
• Refer a friend or colleague
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

Prescrire's other websites

In Prescrire's Spotlight

Covid-19 and ivermectin: many trials, few results, no proven efficacy  NEWS UPDATE  The antiparasitic drug ivermectin has been shown to have in vitro activity against Sars-CoV-2. What are the main results available in early February 2021 from comparative clinical trials of ivermectin in the treatment and prevention of covid-19? 13 February 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ The ChAdOx1 nCoV-19 covid-19 vaccine from AstraZeneca: great uncertainty over its efficacy  NEWS UPDATE  Unlike the first two covid-19 vaccines authorised in Europe, which are messenger RNA vaccines, the covid19 vaccine ChAdOx1 nCoV-19, developed by the University of Oxford and the pharmaceutical company AstraZeneca, is a "viral vector" vaccine. What are the main data available in late January 2021 from the clinical trials of this new vaccine? 29 January 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Covid-19 : Follow Prescrire's independent, evidence-based analysis of the pandemic  COVID-19  Prescrire's editors are publishing an ongoing series of news updates featuring independent analysis of developments related to the covid-19 pandemic. Useful and practical information, to help healthcare professionals gain a clear and balanced view. 13 February 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Covid-19: a recap of treatment options. From Prescrire's comprehensive year-end review FEATURED REVIEW Very large amounts of data about covid-19 were published over the past year. As they became available, Prescrire sorted through to determine just which data were useful for the treatment and prevention of the disease. Full review (3 pages) available for download by subscribers. 1 March 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ In the March issue of Prescrire International: polatuzumab vedotin (Polivy°) and large B-cell lymphoma FREE DOWNLOADPolatuzumab vedotin has been granted conditional European marketing authorisation for certain patients with relapsed or refractory diffuse large B-cell lymphoma. How do Prescrire's editors rate this option? Full text available for free download. 1 March 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Doing one's job EDITORIALThe entire health system should be able to count on pharmaceutical companies to do their job, no more, no less. When the roles within the system become blurred, the quality of health care and patients' freedom to choose according to their needs both suffer. 1 March 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Annual Prescrire Awards for 2020: 3 winning drugs, including the first "Pilule d'Or" in 6 years The independent French medical journal Prescrire has published its annual Awards for drugs, drug packaging and information provided by drug companies in 2020. Two drugs made the "Honours List", and Prescrire's "Pilule d'Or" (Golden Pill) was awarded for the first time in 6 years. 1 March 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Atopic eczema: avoid tacrolimus (Protopic° and other brands) and pimecrolimus (Elidel°) In addition to avoiding factors causing skin irritation, the first-line treatment of atopic eczema is still based on application of an emollient and a topical corticosteroid. 1 March 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Dry eye: sometimes drug-induced The daily lives of many patients are affected by discomfort and visual disturbances, or even ocular lesions, associated with dry eye syndrome. Drugs are sometimes to blame. 1 March 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Comparative trials: an ethical issue Mounting evidence that hydroxychloroquine (Plaquenil°) lacks the efficacy expected in covid-19 has shown the medical and ethical risks of using drugs on the basis of inadequate evidence. 1 March 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Prescrire’s response to the European Commission consultation on a "European Health Emergency Preparedness and Response Authority"  ADVANCING HEALTHCARE POLICY  The Covid-19 pandemic has illustrated the need for enhanced EU action and coordination in response to cross-border health threats. In its response to the public consultation, Prescrire calls for: an independent, public-driven agency with clear public health missions; effective governance process and structure; public funding, with conditions to safeguard affordability, accessibility, availability and transparency. 23 February 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Enjoy these features, and more, in our upcoming issues COMING SOON Larotrectinib and cancers with an NTRK gene fusion • Valproic acid: an endocrine disruptor? • Treatment of relapsed or refractory multiple myeloma • Drug shortages... > Subscribe now 1 March 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ "Top Texts of 2020", from the editors of Prescrire International  FREE SPECIAL EDITION  Check out this brand new sampling of texts from Prescrire International, a wholly independent monthly journal written by and for healthcare professionals. Inside, top articles from our "New Products", "Adverse Effects" and "Reviews" sections, plus our annual update of drugs to avoid. > Click here for your free copy 1 March 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Follow Prescrire International on Facebook and Twitter Keep up with the latest from Prescrire's editors, and support our values of independence and quality information, first and foremost in the interest of patients. Click here to > Follow us on Facebook or > Follow us on Twitter 1 November 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Subscribe today for full access to top-quality content from Prescrire International Subscribe now Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 150 euros (less for students and residents of lower-income countries). 1 November 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Receive the free, monthly "Independent Drug & Healthcare Newsletter" Click here to sign up for the free Newsletter from the editors of the non-profit journal Prescrire International, with highlights of the contents of the latest issue. 1 November 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Drugs to avoid, in the name of better patient care   DRUGS TO AVOID - 2021 UPDATE  Independent French medical journal Prescrire has published its annual update of drugs to avoid. The goal is to make it easier to choose high-quality care, and to prevent disproportionate harm to patients. > Read more

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Read more All the subjects in Prescrire's Spotlight >

• Sitemap |
• Terms of use |
• Contact
• |Top of page